Clinical Trials Logo

Sarcoma Metastatic clinical trials

View clinical trials related to Sarcoma Metastatic.

Filter by:
  • None
  • Page 1

NCT ID: NCT06211257 Recruiting - Clinical trials for Locally Advanced Soft Tissue Sarcoma

Superiority Trial Evaluating Digitalized Information Media for Patients With Advanced Sarcomas Receiving Second Line Treatment.

ePPS-2202
Start date: May 29, 2024
Phase: N/A
Study type: Interventional

ePPS-2202 is a study designed to evaluate the benefits of a dematerialised personalised care plan (PCP) compared to standard information/PCP for patients with advanced sarcomas receiving second-line treatment. Participants will be randomised to an experimental group or a control group. Patients in the experimental group will receive the dematerialised PCP in addition to the standard PCP while patients in the control group will receive the standard PCP alone. All patients will be followed until the end of second-line treatment, the start of a new line of treatment, or until the 24-month follow-up.

NCT ID: NCT04910126 Recruiting - Soft Tissue Sarcoma Clinical Trials

Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma

Start date: November 12, 2020
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of the combination of adriamycin and Camrelizumab in the first-line treatment of advanced soft tissue sarcoma

NCT ID: NCT04076579 Active, not recruiting - Sarcoma Clinical Trials

Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

Start date: March 17, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well trabectedin and olaparib work in treating patients with sarcoma that cannot be removed by surgery or has spread to other places in the body. Drugs used in chemotherapy, such as trabectedin, work in different ways to stop the growth of tumor cells, either by killing cells, stopping them from dividing or stopping them from spreading. Olaparib may stop the growth of tumor cells by blocking pathways responsible for repairing damaged cells. Giving trabectedin and olaparib may shrink or stop the tumor from growing.